Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XomaZyme-791
- Development stage
- Unknown
- Lead developer
- XOMA
- Modality
- Recombinant Proteins and Enzymes, Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
XomaZyme-791 is an immunotoxin composed of the ricin A chain conjugated to a murine monoclonal antibody (MoAb 791T) that specifically binds to a 72 kDa glycoprotein expressed on human colorectal carcinoma, ovarian carcinoma, and osteogenic sarcoma cells. The mechanism of action involves the targeted delivery of the ricin A chain toxin to tumor cells via antibody-mediated binding; once internalized by cancer cells, the ricin A chain inactivates ribosomes and halts protein synthesis, leading to cell death. This agent was developed as an experimental therapy for solid tumors such as metastatic colorectal cancer[2][3][7]. Clinical studies have focused on its use in oncology settings where conventional therapies are limited.
- Other names
- XomaZyme-791XomaZyme791XomaZyme 791XMMCO-791/RTA791T immunotoxin
02
Targets
TAG-72
Beyond the preview
Go deeper on XomaZyme-791.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XomaZyme-791.